Various studies have proven that the levels of this prosurvival protein, taken into account together with clinicopathological characteristics, have prognostic value for patients with cancer, and MCL1 may be a prognostic biomarker for patients with certain types of cancer [5]. This evidence concerns the gene MCL1 and cancer.